Background {#Sec1}
==========

Pseudotumors associated with metal-on-metal hips are common in resurfacing and total hip arthroplasty (THA). Pseudotumors, including asymptomatic cases, have been reported in up to 69 % of cases when patients are screened after metal-on-metal hip resurfacing or THA \[[@CR1]--[@CR9]\]. Pseudotumors can be asymptomatic or have a wide variation in presentations, not only with pain and discomfort in the groin, but also with cup loosening or nerve palsy \[[@CR2], [@CR4], [@CR5], [@CR7], [@CR8]\]. In addition, the prevalence of pseudotumors was reported to be similar in well-functioning patients and patients with painful metal-on-metal hip implants \[[@CR10]\]. Magnetic resonance imaging (MRI) provides sensitive screening of pseudotumors following metal-on-metal hip implants. MRI is ideally suited for assessment of these patients and complements standard clinical evaluation \[[@CR11], [@CR12]\].

It remains unclear whether asymptomatic patients with pseudotumors become symptomatic and whether the presence of symptoms correlates with MRI findings and patients' characteristics. The purpose of this study was to identify the factors associated with symptomatic and asymptomatic pseudotumors. We hypothesized that the pseudotumors would be larger in symptomatic patients and asymptomatic pseudotumors has specific factors not to become symptomatic.

Methods {#Sec2}
=======

A total of 239 large-diameter, metal-on-metal THAs were performed in 222 patients. THA devices included 108 Cormet (Corin, Cirencester, UK), 80 Ultamet (DePuy, Warsaw, IN), and 51 Conserve Plus (Wright Medical Technology, Arlington, TN). Screening for pseudotumors was performed using MRI after THA. Pseudotumors were defined as any mass around the hip joint. MRI studies were conducted in all subjects regardless of symptoms to ensure that asymptomatic pseudotumors could be detected. The mean time at last follow-up with MRI was 49 months (22--85 months). A 1.5-T scanner was used with T1-weighted spin-echo (SE), T2-weighted SE, and short tau inversion recovery (STIR) sequences (Signa; General Electric Healthcare, Waukesha, WI, USA) (Table [1](#Tab1){ref-type="table"}). An eight-channel cardiac coil (GE Healthcare) was used. Two-dimensional fast spin echo images were obtained using modifications to the pulse parameters to reduce susceptibility artifact. A wider receiver bandwidth and oversampling in the frequency encoding axis were used to increase the strength of the readout gradient \[[@CR13]\].Table 1Pulse sequence protocol for MR imagingCoronal T1 SECoronal T2 SECoronal STIRAxial T1 SEAxial STIRRepetition time (msec)450--5603000--40905000--7600450--5005000--7600Echo time (msec)9--1494--10069--7713--1469--77Inversion time (msec)150150Receiver band-width (Hz per pixel)300--400300--400300--400300--400300--400Flip angle (degrees)9090909090Field of view (mm)340 × 340340 × 340340 × 340340 × 340340 × 340Matrix512 × 512512 × 512512 × 512512 × 512512 × 512Section thickness (mm)4--64--64--64--64--6

Fifty-seven patients with 62 affected hips showed pseudotumors (28 Cormet, 19 Ultamet, and 15 Conserve Plus). There were 45 women with 49 hips and 12 men with 13 hips, with a mean age of 64 years and a mean body mass index (BMI) of 23.9 kg/m^2^. The primary diagnoses were osteoarthritis in 54 patients and rheumatoid arthritis in three patients. Sixteen hips had symptomatic pseudotumors with pain, and 46 hips were asymptomatic. Fourteen of 16 symptomatic hips had undergone revision surgery. Symptoms disappeared after revision in all revised patients. The Cormet cup was made of cobalt-chromium alloy with a titanium porous coating for bone ingrowth. The Pinnacle cup, which was made of titanium alloy, was a modular cup with a titanium porous coating; a cobalt-chromium alloy liner was inserted in the cup. The Conserve Plus cup was made of a cobalt-chromium alloy with a cobalt-chromium alloy bead coating. The head was made of cobalt-chromium alloy in all implants. The mean head diameter of Cormet devices was 43 mm (40--48 mm). The head diameter for Pinnacle devices was 36 mm in all hips. The mean head diameter of Conserve Plus devices was 47 mm (44--52 mm). The acetabular component inclination angle was measured on anteroposterior pelvic radiographs. The inclination angle was defined as the angle between the line joining the inferior teardrop points and the axis of the opening of the acetabular component. Acetabular anteversion was measured with computer software (Advanced CasePlan Digital Templating Planning Software, Stryker Orthopedics, Mahwah, NJ) \[[@CR14]\]. The mean inclination angle of the cup was 44° (23--70°), and the mean anteversion angle was 14° (4--25°).

Pseudotumor size was determined on MRI by one investigator (MH), manually outlining the greatest axial size of the mass. This investigator had 4 years of experience in MRI evaluation of postoperative hips. The area of the pseudotumor was measured using computer software (EV Insite Version 2.10.7.108; PSP Corporation, Tokyo, Japan) (Fig. [1](#Fig1){ref-type="fig"}). The scan areas were obtained from the same image for each longitudinal comparison. The anatomical position of pseudotumors was divided into anterior position and posterolateral position. When both positions were involved, the hip was classified based on the larger size. Pseudotumors were located in the anterior position in 23 hips and in the posterolateral position in 39 hips. Types of pseudotumors were divided into two types \[[@CR4], [@CR15]\]: cystic type (35 hips) and mixed solid cystic type and solid type without a cystic component (27 hips) (Fig. [2](#Fig2){ref-type="fig"}). The follow-up study of pseudotumors was determined using MRI in 33 patients. The mean time between the first MRI and the follow-up MRI was 24 months (8--66 months). Whether asymptomatic patients with pseudotumors became symptomatic was examined, and the growth rate of pseudotumors was determined from follow-up MRIs. The serum cobalt and chromium ion levels were measured closest to the date of the MRI in 38 patients after unilateral THA (11 symptomatic and 27 asymptomatic patients). Cobalt levels were assayed using Inductively Coupled Plasma Mass Spectrometry (Perkin-Elmer SCIEX Elan 6100 DRC ICPMS system; Perkin-Elmer Instruments, Norwalk, CT) at Mayo Medical Laboratories (Rochester, MN), and chromium levels were assayed using a graphite furnace atomic absorption spectrometer (Z-5700; Hitachi Ltd., Tokyo, Japan) with polarization-Zeeman absorption at Mitsubishi Chemistry Medience Co., Ltd. (Tokyo, Japan). Detection limits for each ion were 0.2 μg/L \[[@CR16]\]. This study was approved by the local institutional review board, and all patients provided their informed consent.Fig. 1Measurement of pseudotumor size on a magnetic resonance image by manually outlining the greatest size of the mass using computer software Fig. 2Magnetic resonance images (transverse short tau inversion recovery images) showing pseudotumors (*arrows*) of the cystic type (**a**) and the mixed solid cystic type (**b**)

Statistical analysis {#Sec3}
--------------------

The Mann-Whitney U test was used to compare age, BMI, femoral head diameter, acetabular cup inclination and anteversion angles, time of MRI screening, pseudotumor size, and serum cobalt and chromium ion levels between symptomatic and asymptomatic patients. The chi-squared test and Fisher's exact test were used to compare sex, position of pseudotumors, pseudotumor type, and changes of pseudotumor size between the groups. Multiple regression analysis was also performed. Statistical significance was set at *P* \< 0.05. Statistical analysis was performed using SPSS version 22 (SPSS, Inc, Chicago, IL).

Results {#Sec4}
=======

The mean BMI was 25.4 kg/m^2^ in symptomatic patients and 23.4 kg/m^2^ in asymptomatic patients; higher BMI was associated with symptoms (*P* = 0.036, Table [2](#Tab2){ref-type="table"}). Symptomatic pseudotumors were significantly larger (three-fold) than asymptomatic pseudotumors (*P* = 0.003, Table [2](#Tab2){ref-type="table"}). Pseudotumors located in the anterior position were associated with symptoms (*P* = 0.032, Table [2](#Tab2){ref-type="table"}), as were mixed solid cystic and solid type pseudotumors (*P* = 0.007, Table [2](#Tab2){ref-type="table"}). Other factors were not significantly different between the groups (Table [2](#Tab2){ref-type="table"}). The growth rate of asymptomatic pseudotumors was 132 ± 502 mm^2^/year. On multivariate analysis, a significant difference was seen only in size (*R* ^2^ = 0.298, *P* = 0.031). BMI (*P* = 0.100), position (*P* = 0.116), and type (*P* = 0.161) showed no significant differences on multivariate analysis. No asymptomatic patients with pseudotumors became symptomatic during the MRI follow-up period.Table 2Risk factors associated with symptomatic pseudotumorsSymptomaticAsymptomatic*P*Sex Female15340.154 Male112Age (years)^a^63.164.10.803BMI (kg/m^2^)^a^25.423.40.036Head diameter (mm)^a^42.641.70.454Cup inclination (°)^a^45.243.50.790Cup anteversion (°)^a^14.113.30.494Time of MRI screening (months)^a^45.749.70.359Pseudotumor size (mm^2^)^a^18126420.003Position of pseudotumor Anterior10130.019 Posterolateral633Pseudotumor type Cystic4310.007 Mixed cystic solid and solid1215Change of pseudotumor size Decreased260.083 Increased48 No change013Cobalt level (μg/L)^a^11.78.80.176Chromium level (μg/L)^a^10.36.20.171^a^mean

Discussion {#Sec5}
==========

Pseudotumors following metal-on-metal hip arthroplasty are an important problem. Early and accurate diagnosis of a pseudotumor is crucial to plan further management of this potentially devastating complication because late revision surgeries can have poor outcomes \[[@CR17], [@CR18]\]. However, previous longitudinal studies demonstrated disappearance of pseudotumors \[[@CR19]--[@CR21]\]. We confirmed that pseudotumors frequently change in size \[[@CR22]\] on longitudinal assessment with MRI after metal-on-metal THA. Some patients with pseudotumors following metal-on-metal arthroplasty have severe soft tissue damage resulting in early failure. In contrast, some patients with pseudotumors have no symptoms. Asymptomatic pseudotumors have been reported to occur in 27 to 73 % of cases (Table [3](#Tab3){ref-type="table"}) \[[@CR2], [@CR7], [@CR8], [@CR10]\]. It is desirable to determine the characteristics of symptomatic pseudotumors.Table 3Prevalence of symptoms with pseudotumors and associated factorsAuthors*n*Symptomatic (%)Asymptomatic (%)Factor associated with symptomsHart et al. \[[@CR10]\]3417 (50)17 (50)Sutphen et al. \[[@CR8]\]7031 (44)39 (56)Elevated serum cobalt levelBisschop et al. \[[@CR2]\]4011 (28)29 (73)Larger pseudotumorsNawabi et al. \[[@CR7]\]5540 (73)15 (27)Larger pseudotumorsCurrent study6216 (26)46 (74)Larger pseudotumors

Chang et al. \[[@CR3], [@CR23]\] reported that pseudotumor size was not associated with symptoms. However, other studies \[[@CR2], [@CR7]\] demonstrated larger pseudotumors in symptomatic patients, similar to the present study's finding. Hart et al. \[[@CR10]\] confirmed that the presence of a fluid-filled lesion (cystic type) visible on MRI had less clinical importance, but they were concerned about solid pseudotumors. Hauptfleisch et al. \[[@CR24]\] reported that predominantly solid (mixed type) pseudotumors were associated with a higher likelihood of symptoms than cystic pseudotumors. The present results support these findings. In terms of metal ion concentrations, a recent study by Sutphen et al. \[[@CR8]\] demonstrated that elevated serum cobalt levels might be associated with symptoms. However, the present study, as well as the study by Chang et al. \[[@CR23]\], showed no significant correlation with symptoms.

Guidelines recommending follow-up of asymptomatic patients undergoing metal-on-metal hip arthroplasty have already been published \[[@CR25]\]; however, the indications for operative revision have yet to be established. In our institution, revision is recommended for patients with painful hips with pseudotumors.

Pseudotumors observed in asymptomatic patients could eventually become symptomatic \[[@CR23]\]. One of the strengths of this study was that the follow-up study of asymptomatic patients with pseudotumors was observed, and no asymptomatic patients with pseudotumors became symptomatic during the MRI follow-up period.

This study has some limitations. First, a small number of patients was studied. Second, the follow-up period was short. A longer follow-up study will be necessary. Third, there is no standardized definition of pseudotumor in the literature. It is likely that, in some patients with cystic pseudotumor, its presence is not a result of an abnormal tissue reaction, but rather fluid accumulation \[[@CR22]\].

Conclusions {#Sec6}
===========

Higher BMI, larger pseudotumor size, pseudotumors in the anterior position, and mixed solid cystic and solid type of pseudotumors were predictors of symptoms on univariate analyses. For these patients, longer follow-up studies are required. However, larger size was the only significant factor for symptoms on multivariate analysis, and our first hypothesis was verified. If asymptomatic patients with pseudotumors are asymptomatic at follow-up MRI, especially with pseudotumors small in size in the posterolateral position, and of cystic type, further MRI follow-up may not be indicated because these patients have less chance to become symptomatic. Asymptomatic pseudotumors with small in size in the posterolateral position, and of cystic type could be specific factors not to become symptomatic. And our second hypothesis was verified.
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